1. Home
  2. ACET vs DRIO Comparison

ACET vs DRIO Comparison

Compare ACET & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.73

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Logo DarioHealth Corp.

DRIO

DarioHealth Corp.

N/A

Current Price

$7.50

Market Cap

61.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
DRIO
Founded
1947
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.3M
61.8M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
ACET
DRIO
Price
$7.73
$7.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$48.33
$35.00
AVG Volume (30 Days)
136.8K
15.5K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1559.02
EPS
N/A
10.12
Revenue
N/A
$7,394,000.00
Revenue This Year
N/A
$20.27
Revenue Next Year
N/A
$47.58
P/E Ratio
N/A
$0.73
Revenue Growth
N/A
43.02
52 Week Low
$0.46
$0.38
52 Week High
$9.05
$17.74

Technical Indicators

Market Signals
Indicator
ACET
DRIO
Relative Strength Index (RSI) 52.19 45.73
Support Level $6.28 $7.37
Resistance Level $8.46 $9.46
Average True Range (ATR) 0.47 0.46
MACD 0.03 0.11
Stochastic Oscillator 57.30 69.85

Price Performance

Historical Comparison
ACET
DRIO

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Share on Social Networks: